CS12192 is a highly selective JAK3 kinase inhibitor that also partially inhibits JAK1 and TBK1 kinases, independently developed by Chipscreen Biosciences with global patent protection.

Pre-clinical studies indicate that CS12192 has significant pharmacodynamic activity in various disease models, such as rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, psoriasis, and graft-versus-host disease (GVHD). Unlike other commercially available JAK inhibitors, CS12192 not only effectively suppresses the inflammation caused by over-activation of immune cells, but also reduces tissue infiltration of immune cells through the inhibition of TBK1 activity, leading to better efficacy and safety. For these reasons, CS12192 is expected to provide a new and differentiated alternative treatment for autoimmune diseases.

Figure. Mechanism of action of CS12192

• In March 2020, the investigational new drug (IND) application for CS12192 was accepted by the Center of Drug Evaluation (CDE) of the NMPA.
• In September 2020, the first subject was enrolled in the clinical trial of CS12192, marking the official start of trials of the first therapeutic drug developed by Chipscreen Biosciences for autoimmune diseases.
• In Aug. 2021, the Investigational New Drug (IND) application of CS12192 for the treatment of Graft-Versus-Host Disease (GVHD) was approved by the U.S. Food and Drug Administration (FDA).
• Chipscreen Biosciences has completed the phase I clinical study of CS12192 in China.